Dashboard

Telix Pharmaceuticals Limited

TLXNASDAQ

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$3.5B

Price$10.2252w $6.41 – $17.48

Conviction4/ 5

Revenue (TTM)$1.2B

Revenue growth YoY+54.9%

P/E (trailing)—

Gross margin50.7%

Operating margin2.1%

Net margin-0.9%

52w price change-39.2%

Next earnings—

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

Jul 21
Financial resultsSEC
6-K filing containing Q2 2026 trading update for foreign issuer.
Jul 2
Trial initiationSEC
Telix Pharmaceuticals filed Form 6-K covering ProstACT GLOBAL P trial update.
May 29
OtherClinicalTrials.gov
Telix 18F-Floretyrosine Expanded Access Program (NCT06743100) status updated to NO_LONGER_AVAILABLE.
May 29
OtherClinicalTrials.gov
89Zr-DFO-girentuximab EAP status updated to NO_LONGER_AVAILABLE (NCT06090331).
May 27
Trial initiationClinicalTrials.gov
Phase 3 ProstACT Global trial (NCT06520345) of 177Lu-TLX591 + SOC vs SOC in mCRPC now recruiting
May 21
OtherSEC
Foreign issuer 6-K filed with AGM results.
May 15
Trial readoutClinicalTrials.gov
Telix-sponsored trial NCT07238322 ([18F]FET PET glioma characterization) status updated to COMPLETED.
May 14
Trial initiationClinicalTrials.gov
Phase 1 trial NCT07197645 initiated for samarium analgesia in end-stage cancerous bone pain; recruiting status
May 6
OtherSEC
SEC Form 4 filing on change in beneficial ownership.
May 5
Trial initiationClinicalTrials.gov
Phase 1b/2 trial (NCT05663710) of 177Lu girentuximab + cabozantinib + nivolumab in advanced clear cell RCC now recruiting; sponsor MD Anderson

Not financial advice — research and opinion only. Disclosures